$119.12
0.24% yesterday
Nasdaq, Apr 28, 10:00 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock News

Negative
Seeking Alpha
4 days ago
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Neutral
GlobeNewsWire
14 days ago
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4 * ) non-carriers or heterozygotes with confirmed amyloid pathology
Positive
Reuters
14 days ago
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Neutral
Investors Business Daily
19 days ago
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
Positive
Seeking Alpha
20 days ago
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline, despite the market's current undervaluation. Sage's Zuranolone shows strong market traction in PPD, with significant insurance coverage...
Neutral
GlobeNewsWire
27 days ago
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review ...
Negative
Proactive Investors
about one month ago
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax cond...
Negative
Market Watch
about one month ago
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today